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Abstract 
Background: The lack of background disease incidence rates in sub-Saharan countries where the RTS,S/AS01E 
malaria vaccine is being implemented may hamper the assessment of vaccine safety and effectiveness. This study 
aimed to document baseline incidence rates of meningitis, malaria, mortality, and other health outcomes prior to vac-
cine introduction through the Malaria Vaccine Implementation Programme.
Methods: An ongoing disease surveillance study is combining prospective cohort event monitoring and hospital-
based disease surveillance in three study sites in Ghana and Kenya. An interim analysis was performed on the pro-
spective cohort in which children were enrolled in two age-groups (the 5 to 17 months or 6 to 12 weeks age-group), 
capturing data in the framework of routine medical practice before the introduction of the malaria vaccine. Incidence 
and mortality rates were computed with 95% confidential intervals (CI) using an exact method for a Poisson variable.
Results: This analysis includes 14,329 children; 7248 (50.6%) in the 6 to 12 weeks age-group and 7081 (49.4%) in the 
5 to 17 months age-group. In the 5 to 17 months age-group (where the malaria vaccine was planned to be subse-
quently rolled out) the meningitis, malaria, severe malaria and cerebral malaria incidences were 92 (95% CI 25–236), 
47,824 (95% CI 45,411–50,333), 1919 (95% CI 1461–2476) and 33 (95% CI 1–181) per 100,000 person-years, respec-
tively. The all-cause mortality was 969 (95% CI 699–1310) per 100,000 person-years.
Conclusion: Incidence estimates of multiple health outcomes are being generated to allow before-after vaccine 
introduction comparisons that will further characterize the benefit-risk profile of the RTS,S/AS01E vaccine.
Trial registration: clinicaltrials.gov NCT02374450.
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Background
Despite remarkable progress in reducing the global bur-
den of disease due to malaria, there were an estimated 
228 million cases of malaria in 2018 and 405,000 malaria 
deaths globally, of which 380,000 occurred in the Afri-
can region [1]. Plasmodium falciparum caused 99.7% of 
malaria cases, and children aged < 5 years were the most 
vulnerable age-group, accounting for 272,000 (67%) of 
global malaria deaths in 2018 [1]. Without additional 
tools such as vaccines, the World Health Organization 
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(WHO) 2030 global targets of achieving at least a 90% 
reduction in malaria incidence and deaths compared to 
2015 levels, may not be met [2].
RTS,S/AS01E is a pre-erythrocytic P. falciparum 
malaria vaccine developed for routine immunization of 
infants and children living in malaria-endemic countries, 
and is the first complementary tool to be implemented 
under the Global Technical Strategy for Malaria, 2016–
2030. RTS,S/AS01E received a positive scientific opinion 
from the European Medicines Agency in 2015 [3]. Later 
that year the WHO recommended pilot implementa-
tion of routine RTS,S/AS01E vaccination in sub-Saharan 
Africa (SSA), administering three doses to children aged 
5 to 9 months in areas of moderate-to-high malaria trans-
mission, with a fourth dose 15 to 18  months later [4]. 
This pilot implementation will provide more clarity on 
uncertainties related to programmatic feasibility, impact 
and safety of the vaccine in routine use [4].
In 2019, RTS,S/AS01E was introduced in selected 
areas of Ghana, Kenya, and Malawi through national 
immunization programmes in the framework of the 
WHO-commissioned Malaria Vaccine Implementation 
Programme (MVIP) [5]. The MVIP is evaluating the vac-
cine’s public health impact in the context of routine use 
and will inform policy about its potential deployment 
on a broader scale. As part of this evaluation, GSK has 
committed to conduct a post-approval plan (PAP) in 
the pilot implementation areas to further assess vaccine 
safety, effectiveness and impact. Specific safety outcomes 
of interest included those identified during the Phase III 
clinical trial: an imbalance in meningitis and cerebral 
malaria cases between RTS,S/AS01E and control vac-
cine groups in children that started vaccination at 5 to 
17 months of age [6], and across both age groups a higher 
mortality in girls vaccinated with RTS,S/AS01E versus 
girls vaccinated with control vaccines not explained by 
differences in risk factors, causes of death, or time to 
death. Detailed evaluation of these events and absence of 
a biological plausible explanation for a causal relationship 
to RTS,S/AS01E suggest that these observations were 
likely chance findings, possibly due to a low mortality 
rate in girls who received control vaccines, or low rates of 
meningitis in the control group [6].
Limited or absent healthcare and disease surveillance 
infrastructure, and the lack of robust disease incidence 
data in SSA before RTS,S/AS01E implementation [7], 
hamper the assessment of vaccine safety, effectiveness 
and impact. For this reason, the PAP design includes a 
before-after comparison in which data collected prior 
to (pre-vaccine introduction study; NCT02374450) and 
after (post-vaccine introduction study; NCT03855995) 
vaccine introduction are compared. Both studies are 
observational and follow a cohort study design to 
estimate incidence rates of meningitis, malaria, selected 
rare events (referred to here as adverse events of special 
interest [AESI]), other events that lead to hospitaliza-
tion, and mortality in children aged less than 5 years. The 
present paper summarizes the interim results of this pre-
vaccine introduction study that has been conducted so 
far in Ghana and Kenya in children not vaccinated with 
RTS,S/AS01E. The end of study results will be disclosed 
in a separate publication.
Methods
Study design and population
This pre-vaccine introduction study is a disease sur-
veillance study with prospective cohort event moni-
toring including active surveillance of outpatient and 
inpatient visits by each enrolled study participant and 
scheduled home visits. In addition, hospital-based dis-
ease surveillance is organized in the entire study area 
for infants and young children not enrolled in the pro-
spective cohort. The present interim results are limited 
to the analysis of data collected through the prospec-
tive cohort monitoring in which subjects are enrolled 
in two groups (either the 5 to 17  months or the 6 to 
12  weeks age-groups) corresponding to the two age-
groups evaluated in the RTS,S/AS01E Phase III study 
[8]. Those age-groups differ in the way their active sur-
veillance is organized i.e., 10 home visits are organized 
according to the diphtheria-tetanus-pertussis-hepatitis 
B-Haemophilus influenzae (DTP-HepB-Hib) vaccina-
tion schedule for the 6 to 12 weeks age-group, or from 
5  months of age (according to a schedule mimicking 
administration of RTS,S/AS01E, and referred to hereaf-
ter as the ‘virtual primary vaccination schedule’) for the 
5 to 17 months age-group (Additional file 1). The chil-
dren, distributed equally between the two age-groups, 
were recruited into the prospective cohort from three 
study sites (Kintampo and Navrongo in central and 
northern Ghana, respectively; Kombewa in Kenya) 
from January 2016 until June 2018.
Study objectives
The study objectives are to estimate the incidence of 
AESI (listed in Additional file  2), meningitis (aetiology-
confirmed, probable, and clinically suspected meningi-
tis), malaria (any, uncomplicated, severe, and cerebral 
malaria), other events leading to hospitalization, all-
cause and malaria-attributable mortality rates (overall 
and by gender), and to describe causes of death (overall 
and by gender) in children prior to implementation of 
RTS,S/AS01E. Case definitions are described in Addi-
tional file 2. At-risk periods after DTP-HebB-Hib vacci-
nation for the 6 to 12 weeks age group and virtual at-risk 
periods after a virtual vaccination mimicking RTS,S/
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AS01E administration for 5 to 17 months age group were 
defined for each study outcome (Additional file 3).
Study procedures
This study captures data generated in the framework of 
routine medical practice, which includes medical history, 
clinical diagnosis and results of locally conducted labo-
ratory tests (referred to as first-line laboratory results). 
Training on pharmacovigilance and the diagnosis of 
AESI and meningitis was provided to all sites. Job aids 
(i.e., field guides with signs and symptoms of AESI and 
meningitis, and guidelines for diagnosis based on the 
case definition) were also provided, and laboratory test-
ing capacities were enhanced to support case detection 
and ascertainment. For each suspected case of AESI and 
meningitis, a protocol-specified blood sample of 5  ml 
was sent to an external reference laboratory for testing 
(second-line laboratory). For meningitis and neurological 
AESI, when a lumbar puncture was conducted according 
to routine diagnostic practice, an aliquot of cerebrospi-
nal fluid (CSF) was sent to the second-line laboratory if a 
sufficient quantity was available after first-line laboratory 
testing.
All cases of meningitis, cerebral malaria, and ambigu-
ous cases of any other endpoint were reviewed by a panel 
of external experts (i.e., medical professionals with var-
ied backgrounds who independently reviewed the cases). 
Cause of death was either established from the medi-
cal records when occurring at a healthcare facility, or 
through verbal autopsy for children who died in the com-
munity [9].
Statistical analysis
The total enrolled cohort of the interim analysis included 
all children enrolled in the prospective cohort who, by 05 
October 2018, had reached the study home visit num-
ber five which is planned approximately 6 months after a 
3-dose schedule of DTP-HepB-Hib for the 6 to 12 weeks 
age-group (primary vaccination schedule) or after a 
virtual 3-dose primary vaccination schedule mimick-
ing RTS,S/AS01E administration for the 5 to 17 months 
age-group (virtual primary vaccination schedule). Study 
participants who reached home visit five after this date 
were excluded. The According-to-protocol (ATP) cohort 
included all children who met eligibility criteria (Addi-
tional file 4), complied with protocol-defined enrolment 
procedures, and who had no elimination criteria during 
the study.
Incidence rates were computed overall and by study 
site, and mortality rates were computed overall, by gen-
der, and by study site using the data collected during a 
follow-up period of approximately 6  months after the 
(virtual) primary vaccination schedule. A 95% confiden-
tial interval (CI) was computed using an exact method 
for a Poisson variable. For the events with an at-risk 
period (Additional file  3), the incidence rate was com-
puted by dividing the number of children reporting at 
least one event within the at-risk period after each (vir-
tual) vaccinated dose by the accumulated at-risk period 
after (virtual) vaccination.
AEs (other than AESI, meningitis or malaria) leading 
to hospitalization and cause of death were coded accord-
ing to the MedDRA preferred terms. Preferred terms of 
other AEs leading to hospitalization were grouped into 
medically relevant categories for the calculation of the 
incidence rates (Additional file 5).
Quality indicators of surveillance
To assess the operational conduct of the study, two qual-
ity surveillance indicators were monitored in health care 
facilities; abscess at the injection site during the 7-day 
period after each dose of the (virtual) primary vaccina-
tion schedule; and foot positional deformation, as defined 
in Additional file 6.
Ethics and consent
The study was conducted in accordance with Good Clini-
cal Practice and Good Pharmacoepidemiology Practices, 
all applicable subject privacy requirements and the guid-
ing principles of the Declaration of Helsinki. The study 
protocol and associated documents were approved by 
relevant Ethical Review Boards (Additional file 7). Writ-
ten or witnessed and thumb written informed consent 
was obtained from the parent/ legal representative of 
each study participant prior to enrolment.
Anonymized individual participant data and study doc-
uments can be requested for further research from www. 
clini calst udyda tareq uest. com.
Results
Study participants
A total of 14,425 children were enrolled in the prospec-
tive cohort, among which 14,329 were part of the ATP 
analysis: 4219 (29.4%) in Kombewa (Kenya), 7952 (55.5%) 
in Kintampo (central Ghana), and 2158 (15.1%) in Nav-
rongo (northern Ghana) (Fig. 1). There were 7248 (50.6%) 
participants in the 6 to 12  weeks age-group and 7081 
(49.4%) in the 5 to 17 months age-group (Fig. 1, Table 1).
In the ATP cohort, the mean age of study participants 
at enrolment was 1.7  months (standard deviation [SD] 
0.3) in the 6 to 12 weeks age-group and 7.7 months (SD 
5.1) in the 5 to 17  months age-group (Table  2). Males 
and females were equally distributed in both age-groups. 
Overall, 9745 (68.0%) study participants resided in rural 
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areas and 12,958 (90.4%) lived less than 5  km from a 
healthcare facility. Details per study site are provided in 
Additional file 8.
A total of 745 participants (5.2%) were hospitalized. 
Among the 5464 (38.1%) participants who had at least 
one outpatient visit, 32 (0.59%) were referred to hospital. 
The percentage of participants diagnosed for each end-
point is provided in Table 3.
In the framework of the MVIP, the RTS,S/AS01E pri-
mary vaccination schedule is currently administered to 
children aged 5 to 9 months. Therefore, the results of the 
ATP cohort presented below focus on the 5 to 17 months 
age-group. Results for the 6 to 12  weeks age-group are 
provided in Table 3 and Additional files 9–11.
Incidence rates of meningitis
Five meningitis cases were initially suspected in the 5 
to 17  months age-group, among which two cases were 
classified as aetiology-confirmed meningitis and two as 
clinically-suspected meningitis. The fifth case was subse-
quently diagnosed as encephalomyelitis (Table  4). None 
of the cases were fatal. CSF was available for three cases. 
There were two cases of aetiology-confirmed menin-
gitis (incidence 46 (95% CI 6–167) per 100,000 person-
years): one due to Staphylococcus aureus, and the other 
(case of co-morbidity with cerebral malaria; see below) 
Fig. 1 CONSORT diagram. KE, Kenya; GH, Ghana; ATP, According to protocol; M, Months; W, Weeks
Table 1 Number of study participants by study site and by study 
group
According-to-protocol cohort
N, total number of study participants by study site
Study site Study group Number of 
participants (%) per 
study site
Kombewa, Kenya N = 4219 6 to 12 weeks 1979 (46.9)
5 to 17 months 2240 (53.1)
Kintampo, Ghana N = 7952 6 to 12 weeks 4297 (54.0)
5 to 17 months 3655 (46.0)
Navrongo, Ghana N = 2158 6 to 12 weeks 972 (45.0)
5 to 17 months 1186 (55.0)
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incorrectly classified as meningitis due to Parvovirus 
before being downgraded to probable meningitis follow-
ing further review by the expert panel after the interim 
analysis, and clarification of laboratory testing results. 
The incidence rate of aetiology-confirmed, probable 
and/or clinically suspected meningitis was 92 (95% CI 
25–236) per 100,000 person-years.
Incidence rates of malaria
A total of 1561 participants (22%) experienced at least 
one episode of malaria (2129 episodes confirmed by rapid 
diagnostic test and/or microscopy) during an outpatient 
visit or a hospitalization. Uncomplicated malaria was 
diagnosed in 1512 children, which corresponds to 97% 
of the total number of malaria events (2059 out of 2129 
episodes). The remaining 3% (70 episodes in 66 children) 
were severe and included two cases of cerebral malaria 
(fatal for one child, while the other child diagnosed with 
cerebral malaria and meningitis, recovered fully). Plas-
modium falciparum was identified in 1747 cases (82%).
The malaria incidence rate was 47,824 (95% CI 
45,411–50,333) per 100,000 person-years (Table  5). The 
incidence rates of uncomplicated and severe malaria 
were 45,905 (95% CI 43,541–48,364) and 1919 (95% CI 
1461–2476) per 100,000 person-years, respectively. The 
cerebral malaria incidence rate was 33 (95% CI 1–181) 
per 100,000 person-years.
Mortality rate
In total, 56 deaths (26 girls and 30 boys) were reported 
due to pneumonia (12 cases), malaria/P. falciparum infec-
tion (11 cases including one case of cerebral malaria), 
malnutrition (five cases), dehydration (four cases), gas-
troenteritis and thermal burn (three cases each), two 
cases each of asphyxia and herbal toxicity, one case each 
of acute chest syndrome, AIDS-related complication, 
anemia, bronchiolitis, HIV infection, infection, acute oti-
tis media, pulmonary tuberculosis, renal insufficiency, 
sepsis, skin infection, sudden infant death syndrome, and 
two cases of death (cause unspecified). Approximately 
29% of deaths occurred during hospitalization. The all-
cause mortality rate per 100,000 person-years was 969 
(95% CI 699–1310), with similar rates in girls (940, 95% 
CI 574–1451) and boys (998, 95% CI 626–1511) (Table 6). 
The rate of malaria-attributable deaths was 231 (95% CI 
111–424) per 100,000 person-years (Table 6).
Incidence rates of AESI
Two AESI were diagnosed in participants in the 5 to 
17  months age-group, one case of intussusception (144 
per 100,000 person-years; 95% CI 4–800), and one case 
of encephalomyelitis occurring outside the at-risk period 
of 6 weeks (no incidence rate calculated). Both AESI led 
to hospitalization, neither was fatal.
Other AEs leading to hospitalization
In the 5 to 17 months age-group, 392 study participants 
(5.5%) experienced 802 other events (i.e., other than 
meningitis, malaria or AESI) that led to their hospitaliza-
tion (Table 3). The most frequently reported other events 
were anaemia, gastroenteritis, and lower respiratory tract 
infection (Table 7 and Additional file 12).
Quality indicators of surveillance
In the 6 to 12 weeks age-group, there were five cases of 
abscess at the injection site after a total of 21,149 DTP-
HepB-Hib doses. No cases were reported in the 5 to 
17  months age-group. No foot positional deformations 
were reported in either group.
Discussion
In the context of the MVIP, the RTS,S/AS01E malaria 
vaccine has recently been included in the Expanded Pro-
grammes on Immunization (EPI) of selected pilot imple-
mentation areas of Ghana, Kenya and Malawi. As RTS,S/
Table 2 Demographic characteristics at study entry by study 
group
According-to-protocol cohort
N, total number of study participants by study site; n, number of study 
participants in each category; SD: standard deviation
6 to 12 weeks 
age-group 
(N = 7248)





Age at informed consent (months)
 Mean ± SD 1.7 ± 0.3 7.7 ± 5.1 4.7 ± 4.7
 Range 0.4–3.0 0.4–18.0 0.4–18.0
Gender, n (%)
 Female 3585 (49.5) 3484 (49.2) 7069 (49.3)
 Male 3663 (50.5) 3597 (50.8) 7260 (50.7)
Neighbourhood of residence, n (%)
 Urban 1320 (18.2) 920 (13.0) 2240 (15.6)
 Semi-rural 1225 (16.9) 1119 (15.8) 2344 (16.4)
 Rural 4703 (64.9) 5042 (71.2) 9745 (68.0)
Distance to health care facility, n (%)
 < 5 km 6588 (90.9) 6370 (90.0) 12,958 (90.4)
 5– < 10 km 543 (7.5) 496 (7.0) 1039 (7.3)
 10– < 20 km 84 (1.2) 149 (2.1) 233 (1.6)
 20– < 30 km 17 (0.2) 42 (0.6) 59 (0.4)
 > 30 km 16 (0.2) 24 (0.3) 40 (0.3)
Closest health care facility, n (%)
 Primary health 
care facility
5135 (70.9) 5165 (72.9) 10,300 (71.9)
 Hospital 2113 (29.2) 1916 (27.1) 4029 (28.1)
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AS01E has not been introduced as part of EPI anywhere 
else in the world, no post-authorization surveillance 
data has been generated so far. The MVIP includes an 
important vaccine evaluation component in which GSK 
is conducting a comprehensive PAP in collaboration with 
African scientific partners. Limited background data on 
the incidence of diseases of interest in the framework of 
this PAP are available in the SSA context. The present 
study enrolled children not vaccinated with RTS,S/AS01E 
in three study sites of moderate-to-high malaria trans-
mission in Ghana and Kenya, countries where RTS,S/
AS01E is being administered in selected areas since 2019. 
The study was designed to document baseline incidence 
data prior to RTS,S/AS01E implementation to allow a 
before-after vaccine introduction comparison, and more 
broadly to help interpretation of pharmacovigilance 
monitoring data after vaccine implementation. Prelimi-
nary study results pertaining to the 5 to 17 months age-
group are discussed here.
Overall, the mortality rate per 100,000 person-years 
observed in the 5 to 17 months age-group was 969 (95% 
CI 699–1310) ranging from 265 (95% CI 32–959) to 1681 
(95% CI 1041–2569) depending on the study site. Even 
though a formal comparison is not possible as age-groups 
and study period differ, those figures are not inconsistent 
with the INDEPTH Network mortality estimates for 
the period 2006 to 2012, ranging from 820 per 100,000 
person-years in children aged 1 to 4 years in Navrongo, 
Ghana, to 7420 per 100,000 person-years in children 
aged 1 to 11 months in Kisumu, Kenya [10]. Overall, no 
marked difference in mortality rate between genders was 
observed.
Across the study sites, the incidence rate of meningi-
tis (including aetiology-confirmed, probable and clini-
cally suspected meningitis) was 92 (95% CI 25–236) per 
100,000 person-years in the 5 to 17  months age-group. 
Of note, antibiotic therapy was initiated one to two days 
before CSF sample collection for two cases, which may 
have affected the CSF testing results and the final case 
classification. Though available data on meningitis inci-
dence in SSA are scarce and clear case definitions are 
often lacking, this figure is in the range of incidence rates 
published for Burkina Faso (between 42 and 101 per 
100,000 person-years in children aged less than 5  years 
for the 2011 to 2015 period) [11].
The incidence of malaria in the 5 to 17  months age-
group was similar between Kintampo, Ghana and 
Kombewa, Kenya (as could be expected based on their 
similar malaria transmission intensity reported pre-
viously [12]) but fourfold lower in Navrongo, Ghana, 
Table 3 Percentage of study participants with final diagnoses for the main interim analysis endpoints
According-to-protocol cohort
AESI: adverse event of special interest; AE: adverse event; N: total number of study participants by study group or by study site; e, number of events reported; n, 
number of study participants in each category; %, percentage of study participants who reported at least one event
The AESI in this study refer to a list of 15 diseases: Acute disseminated encephalomyelitis, Encephalitis, Guillain-Barré syndrome, Generalized convulsive seizure, 
Hypotonic hypo-responsive episode, Intussusception, Hepatic insufficiency, Renal insufficiency, Juvenile chronic arthritis, Stevens Johnson syndrome and toxic 
epidermal necrolysis, Henoch Schonlein purpura, Kawasaki disease, Diabetes mellitus type 1, Thrombocytopenia, Anaphylaxis
a Adverse events other than AESI, malaria or meningitis
6 to 12 weeks Kombewa, Kenya Kintampo, Ghana Navrongo, Ghana Overall
N = 1979 N = 4297 N = 972 N = 7248
e n % e n % e n % e n %
AESI 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Meningitis 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Malaria 479 375 19.0 898 685 15.9 48 43 4.4 1425 1103 15.2
Other  AEa leading to hospitalization 62 38 1.9 439 233 5.4 111 46 4.7 612 317 4.4
All-cause hospitalization 39 39 2.0 268 240 5.6 54 47 4.8 361 326 4.5
5 to 17 months Kombewa, Kenya Kintampo, Ghana Navrongo, Ghana Overall
N = 2240 N = 3655 N = 1186 N = 7081
e n % e n % e n % e n %
AESI 1 1 0.04 1 1 0.0 0 0 0.0 2 2 0.0
Meningitis 3 3 0.1 1 1 0.0 0 0 0.0 4 4 0.1
Malaria 639 505 22.5 1363 938 22.7 127 118 10.0 2129 1561 22.0
Other  AEa leading to hospitalization 119 69 3.1 495 254 6.7 188 78 6.6 802 392 5.5
All-cause hospitalization 85 79 3.5 310 262 7.2 92 78 6.6 487 419 5.9
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emphasizing the need for generating local data when 
assessing vaccine effects. Incidence rates were estimated 
according to the level of disease severity, i.e., uncom-
plicated or severe (including cerebral) malaria, and 
following strict WHO case definitions. As clinical mani-
festations of malaria are highly age-dependent, especially 
in young children, final study results covering a longer 
follow-up period of enrolled children will provide key 
data that will be compared with post-approval data to 
assess both short and long-term vaccine effectiveness 
and impact.
Among the list of 15 defined AESI, only one case of 
intussusception (IS) occurred during the pre-defined 
risk period (14 days in the case of IS). It is not surpris-
ing to observe few AESIs at this stage given that these 
health outcomes are rare and that the current interim 
study results include a short subject follow-up period 
(6 months after the virtual primary vaccination schedule). 
The estimated incidence rate of IS was 144 (95% CI 
4–800) per 100,000 person-years. Although the precision 
around this estimate is low, it is in the range of previously 
published data (mean incidence rate of 74 [range 9–328] 
per 100,000 person-years in children less than 1 year old 
between 1978 and 2012) [13].
The operational conduct of the study was assessed by 
two quality surveillance indicators. The rate of abscess at 
injection site observed for the 6 to 12  weeks age-group 
(24 events per 100,000 DTP-HepB-Hib doses) is within 
the expected range for this vaccine (22 to 108 cases per 
100,000 doses) [14]. The absence of cases in the 5 to 
17 months age-group was not unexpected as that assess-
ment did not follow a real vaccine injection (i.e. virtual 
vaccination schedule mimicking RTS,S/AS01E adminis-
tration). No foot positional deformations were reported 
in either group. As the study participants were around 
6 weeks of age (corresponding to the 1st DTP-HepB-Hib 
Table 4 Incidence rate per 100,000 person-years of meningitis cases
According-to-protocol cohort, 5 to 17 months age-group
N, number of study participants at risk during a follow-up period of approximately 6 months after each dose of the virtual primary vaccination schedule censored at 
the next dose; n, number of cases reported during that follow-up period; CI: confidence interval; M: Months
a One case of aetiology-confirmed meningitis has been downgraded to probable meningitis after the interim analysis (see text for details)
Incidence rate per 100,000 person-years
n Person-years Value (95% 
CI)
Kombewa, Kenya (N = 2111)
 Aetiology-confirmed meningitis 1 1249 80 (2, 446)
 Probable meningitis 0 1249 0 (0, 295)
 Clinically suspected meningitis 2 1249 160 (19, 579)
 Aetiology-confirmed, probable, and/or clinically suspected meningitis 3 1248 240 (50, 703)
 Suspected meningitis ruled out afterward 1 1249 80 (2, 446)
Kintampo, Ghana (N = 3603)
 Aetiology-confirmed  meningitisa 1 2330 43 (1, 239)
 Probable meningitis 0 2330 0 (0, 158)
 Clinically suspected meningitis 0 2330 0 (0, 158)
 Aetiology-confirmed, probable, and/or clinically suspected meningitis 1 2330 43 (1, 239)
 Suspected meningitis ruled out afterward 0 2330 0 (0, 158)
Navrongo, Ghana (N = 1183)
 Aetiology-confirmed meningitis 0 754 0 (0, 490)
 Probable meningitis 0 754 0 (0, 490)
 Clinically suspected meningitis 0 754 0 (0, 490)
 Aetiology-confirmed, probable, and/or clinically suspected meningitis 0 754 0 (0, 490)
 Suspected meningitis ruled out afterward 0 754 0 (0, 490)
Overall (N = 6897)
 Aetiology-confirmed  meningitisa 2 4332 46 (6, 167)
 Probable meningitis 0 4332 0 (0, 85)
 Clinically suspected meningitis 2 4332 46 (6, 167)
 Aetiology-confirmed, probable, and/or clinically suspected meningitis 4 4331 92 (25, 236)
 Suspected meningitis ruled out afterward 1 4332 23 (1, 129)
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vaccination dose) or older at time of enrolment, the 
choice of a congenital anomaly was not appropriate.
This study also generated incidence rates of more fre-
quent conditions affecting children in SSA, such as ane-
mia, gastroenteritis, respiratory infections, and sepsis, for 
which incidence estimates are often lacking [15, 16]. To 
a broader extent, the incidence rates reported here will 
support international efforts to estimate the global bur-
den of diseases, especially in the SSA region.
This study has been designed to detect conditions that 
require access to specific diagnostic tools and expertise 
that is not systematically available in SSA. For this rea-
son, multiple tools have been developed and put in place 
to enhance case detection/ascertainment, e.g., medical 
trainings, job aids, telemedicine support, second-line 
laboratory testing of CSF/serum samples, local labora-
tory support, home visits, and consultation of an external 
expert panel. Among other aspects, those tools have been 
pivotal in enhancing the routine practice of CSF collec-
tion to appropriately investigate cases of suspected men-
ingitis, and to differentiate these with cerebral malaria, 
combining both first and second line laboratory results 
and medical judgement to reach the final diagnosis. 
Despite the strong capacity building and subject follow-
up components of this study, data collection relies on 
routine practice and optimal case detection and ascer-
tainment may not have been reached due to the complex 
setting. Additionally, shortages of medical supplies, lim-
ited radiological and laboratory investigational capacities 
and/or reduced availability of medical personnel during 
strikes and elections are events that may have influenced 
case detection and ascertainment. However, this should 
not affect future vaccine safety and effectiveness assess-
ment as the post-introduction study is based on the same 
design and is conducted in the same conditions.
Conclusion
These preliminary results are key for several reasons: (1) 
they are the backbone of the RTS,S/AS01E PAP, gener-
ating background incidence figures around which the 
before-after vaccine introduction comparison will be 
articulated; (2) they provide baseline figures to support 
pharmacovigilance monitoring of the vaccine; (3) they 
demonstrate the technical and operational feasibility of 
conducting such a large scale prospective cohort study 
with limited pre-existing health care and surveillance 
infrastructures; (4) beyond the RTS,S/AS01E PAP, they 
provide incidence rate estimates of health outcomes for 
which only simulated/modelled figures are usually avail-
able. At the end of both pre- and post-vaccine intro-
duction studies, all subjects enrolled in the prospective 
cohorts will have been followed up until 2 years after the 
fourth scheduled vaccination dose. This time-period will 
cover risks periods after each vaccine dose administra-
tion, as well as assessing vaccine effectiveness and impact 
after the primary vaccination schedule and the booster 
dose.
Table 7 Incidence rate per 100,000 person-year of other adverse 
events
According-to-protocol cohort, 5 to 17 months age-group. Other adverse 
events, AE other than AESI, meningitis or malaria that was diagnosed during 
hospitalization.
Preferred terms of other AEs leading to hospitalization were grouped into 
medically relevant categories (refer to Additional file 5 for more details) for the 
calculation on the incidence rates. N, Number of study participants at risk within 
30 days after each dose of the virtual primary vaccination schedule censored at 
the next dose; n, number of cases reported during that follow-up period
CI: confidence interval; M: Months; ATP: According-to-protocol cohort





Anemia 69 1490 4632 (3604, 5862)
Bacterial Infection 1 1492 67 (2, 373)
Burns 2 1492 134 (16, 484)
Conjunctivitis 1 1492 67 (2, 373)
Gastroenteritis 41 1491 2751 (1974, 3732)
Helminthic infection 2 1492 134 (16, 484)
Lower respiratory tract infection 38 1491 2549 (1804, 3499)
Malnutrition 3 1492 201 (41, 588)
Sepsis 22 1491 1475 (925, 2234)
Skin Infection 3 1492 201 (41, 588)
Upper respiratory tract infection 19 1492 1274 (767, 1989)
Urinary tract Infection 0 1492 0 (0, 247)
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A plain language summary of the study is provided in 
Fig. 2.
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